Liquid Biopsy. New Challenges in the era of Immunotherapy and Precision Oncology

Table of Contents

1. What is precision medicine in oncology?2. Liquid biopsy: a right tool in a right context?3. Liquid biopsy: new challenges in the era of immunotherapy and precision oncology NGS and the other faces of molecular biology4. Current clinically validated applications of liquid biopsy5. Liquid biopsy and immunotherapy: is all that glitter gold?6. Which technology performs better? From sample volume to extraction and molecular profiling7. Early detection screening: myth or reality?8. Molecular tumor board9. Future perspectives

Authors

Antonio Russo Medical Oncology Director, Department of Oncology - A.O.U.P. "P. Giaccone" University Hospital, Italy. Antonio Russo, MD, is a Full Professor of Medical Oncology at DICHIRONS Dept, University of Palermo (Italy). He is President of COMU (the Italian National Board of University Medical Oncologists), Italy. He is author of more than 350 publications in peer-reviewed journals. He focused his studies on liquid biopsy since 2003. Ettore Capoluongo Department of Molecular Medicine and Medical Biotechnologies, Universita Federico II - CEINGE, Biotecnologie Avanzate, Italy. Ettore Capoluongo, PhD, is a Full Professor of Clinical Biochemistry and Clinical Molecular Biology and, Head of Clinical Pathology Dept. Cannizzaro Hospital, Catania (Italy). He has published over 270 publications in peer-reviewed journals. Antonio Galvano Professor of Surgery, Oncology and Stomatology, Universita degli Studi di Palermo | UNIPA?�?Department of Surgery, Oncology and StomaLiquid Biopsy: tology, Italy. Antonio Galvano, MD, PhD is an Associate Professor of Medical Oncology at DICHIRONS Dept, University of Palermo (Italy). He has focused his research efforts on liquid biopsies for cancer prognosis and treatment. Antonio Giordano Director of Sbarro Institute for Cancer Research and Molecular Medicine, and ?Center of Biotechnology ??College of Science and Technology, Temple University, USA. Antonio Giordano, MD, PhD, is the Director at the Sbarro Institute at Temple University, Philadelphia (USA) and a Full Professor at University of Siena, Italy. He is best known for his discovery of cyclins, CDK9, CDK10 and Rb2/p130. He is the president and founder of the Sbarro Health Research Organization (SHRO), Philadelphia (USA). He has published over 600 publications in peer-reviewed journals.